Изосорбид динитрат

Quick links

Choose a section

Quick links to important sections

Advertisements

Изосорбид динитрат

Advertisements
Advertisements

Overview of Изосорбид динитрат

Quick Facts

Property Description
Active ingredient Isosorbide Dinitrate
Form Tablet (oral, sublingual), Extended-release Capsule, Aerosol Spray
Pharmacological class Organic Nitrate, Vasodilator, Antianginal Agent
General purpose Reducing cardiac workload and improving myocardial oxygen supply
Origin Synthetic Compound

What Type of Medicine is Изосорбид Динитрат?

Изосорбид динитрат (Isosorbide Dinitrate) is the official International Nonproprietary Name (INN) for this widely prescribed medication, classified as a synthetic organic nitrate ester. It functions primarily as both a potent vasodilator and a direct antianginal agent based on its powerful systemic effects on the cardiovascular system.

The core identity of the drug is defined by its single active ingredient, Isosorbide Dinitrate. The clinical importance of this substance is supported by pharmacological data regarding its role in modulating blood flow. Common brand names utilizing this active ingredient include Isordil and Iso-Mack.

In What Forms is Изосорбид Динитрат Available?

Isosorbide Dinitrate is supplied in several key dosage forms, reflecting its diverse clinical applicability. These preparations include standard oral tablets, specialized sublingual tablets for a rapid onset of action, and extended-release capsules designed for sustained therapeutic coverage.

The medication's varied formulation options are a differentiating feature. The sublingual tablet form, for instance, allows for quick absorption, a strategy utilized for addressing immediate needs. Certain formulations are designed to produce a swift clinical effect.

What is the General Purpose of This Vasodilator?

The fundamental purpose of Isosorbide Dinitrate is to reduce the demand and strain placed upon the heart muscle. As a vasodilator, it achieves this through two main effects: decreasing the volume of blood returning to the heart (preload) and lowering the resistance the heart must pump against (afterload).

This action, recognized for its hemodynamic results, contributes to the improvement of circulatory dynamics by helping the heart muscle receive an adequate supply of oxygen. This foundational benefit is the core aim of its use in general cardiovascular care.

Regulatory References

  1. Isosorbide - StatPearls - NCBI Bookshelf - NIH
  2. Isosorbide: MedlinePlus Drug Information
Advertisements

What side effects are possible with Изосорбид динитрат?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety considerations for Isosorbide Dinitrate, based on government regulatory and authoritative medical sources. The information is organized by the categories used in official safety documents.


Frequency-Classified Adverse Reactions

Adverse effects are categorized by frequency as documented in regulatory sources:

  • Very Common (Affects 1 in 10 or more people): Headache.
  • Common (Affects 1 to 10 in 100 people): Dizziness, somnolence, low blood pressure (hypotension), including a drop upon standing (orthostatic hypotension), flushing, and a temporary increase in heart rate (tachycardia).
  • Uncommon: Nausea, vomiting, and various skin reactions (e.g., allergic reactions).
  • Very Rare: Heartburn and exfoliative dermatitis.

Serious Safety Considerations and Contraindications

The following are serious or clinically significant risks and limitations documented in official safety profiles:

  • Severe Hypotension and Circulatory Collapse: The medicine can cause severe low blood pressure, potentially leading to circulatory collapse, slow heart rate (bradycardia), or fainting (syncope).
  • Paradoxical Effects: A paradoxical increase in chest pain (angina pectoris) can occur.
  • Absolute Restriction (Contraindication): The use of Isosorbide Dinitrate is strictly prohibited (contraindicated) with certain other medicines, specifically Phosphodiesterase Type 5 (PDE5) inhibitors (used for erectile dysfunction or pulmonary hypertension) and Soluble Guanylate Cyclase (sGC) stimulators. This combination poses a significant risk of life-threatening severe hypotension.

Other Documented Safety Notes

  • Withdrawal Effect: Regulatory documentation notes the risk that suddenly stopping the medicine can provoke angina attacks, indicating a potential hemodynamic rebound effect.
  • Population Specifics: Safety documents note a lack of adequate human studies in pregnant women; animal studies have shown embryotoxicity in rabbits.
Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Isosorbide Dinitrate is defined by official regulatory documents as a serious event that can be fatal and requires immediate medical attention. The clinical presentation is dominated by the drug’s profound vascular effects, necessitating prompt emergency action.


Documented Manifestations and Severe Outcomes

Official prescribing information lists several manifestations of excessive exposure:

  • Cardiovascular: Severe hypotension (a critical drop in blood pressure), tachycardia (fast heart rate), palpitations, and eventual circulatory collapse or syncope (fainting).
  • Neurological: Severe and persistent headache, confusion, vertigo, visual disturbances, and in severe cases, convulsions or signs of raised intracranial pressure.
  • Hypoxic Risk: A life-threatening complication is the potential for Methaemoglobinaemia, which results in impaired oxygen delivery and can lead to cyanosis and cardiac arrest.

Required Emergency Actions

Seek emergency medical attention immediately if overuse is suspected. The regulatory guidance mandates that resuscitation measures must be initiated immediately upon recognizing signs of respiratory or circulatory arrest.

Management is symptomatic and supportive. Procedures may include specific positioning (laying the patient down with legs elevated), administration of oxygen, and intravenous fluid administration to counteract severe hypotension. Patients require careful monitoring of blood pressure and pulse and should remain under clinical observation for a prolonged period.

Advertisements

Therapeutic Uses of Изосорбид динитрат

Isosorbide Dinitrate is used to ease symptomatic discomfort associated with angina (chest pain) and may be part of symptomatic management for conditions like heart failure.

This medication is commonly used to help with the prevention and treatment of angina pectoris, as well as being generally used as an adjunctive therapy for managing the symptomatic burden of chronic congestive heart failure. It is applicable in conditions marked by heightened symptom discomfort, such as in patients with coronary artery disease where symptoms are driven by temporary reduced oxygen supply. The therapeutic benefit provides support that helps ease the overall symptom burden, which includes contributing to managing the frequency and intensity of anginal attacks. In clinical settings, it is often used during phases when symptoms become more noticeable and supportive relief is needed.

“Its role is supporting the patient during difficult episodes by easing distress and contributing to maintaining a sense of stability when symptoms are more noticeable.”


Quick Fact: Support for Cardiac Symptom Clusters

Therapeutic Focus Indication Context Primary Benefit
Ischemic Discomfort Episodic or recurrent chest pain (Angina Pectoris) Is used for managing the frequency and intensity of painful episodes.
Systemic Burden Shortness of breath, congestion (Chronic Heart Failure) Contributes to easing the overall symptom load and symptoms related to systemic imbalance.

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Isosorbide Dinitrate

The eligibility for Isosorbide Dinitrate is determined by regulatory guidelines, primarily classifying populations as contraindicated, restricted, or where use is not established.

Absolute Contraindications

Use is strictly prohibited (contraindicated) for patients with a known hypersensitivity to any organic nitrates. Crucially, the medicine must not be used by any patient concurrently taking Phosphodiesterase type-5 (PDE-5) inhibitors (such as sildenafil) or the soluble guanylate cyclase (sGC) stimulator Riociguat, due to the risk of severe hypotension. Contraindication also applies to patients experiencing acute circulatory failure or cardiogenic shock.

Age and Physiological Restrictions

Population Status per Regulatory Documents
Pediatric Patients (under 18) Safety and effectiveness have not been established (use not recommended).
Geriatric Patients (65 and over) Use requires caution due to a higher likelihood of reduced renal, hepatic, or cardiac function.
Pregnancy Category C status. Use is limited to situations where the potential benefit justifies the potential risk to the fetus.
Lactation Caution is advised as it is unknown if the drug is excreted in human milk.

Eligibility also mandates caution for patients with severe hypotension or conditions like hypertrophic cardiomyopathy.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Isosorbide Dinitrate is predominantly structured by pharmacodynamic potentiation of its vasodilating effects, leading to strictly regulated combinations based on official government documentation.


Contraindicated Combinations

Co-administration is officially Contraindicated with the following drug classes due to the severe risk of hypotension, syncope, or myocardial ischemia resulting from additive vasodilatory effects:

  • Phosphodiesterase Type 5 (PDE-5) Inhibitors: This includes specific agents such as Sildenafil, Tadalafil, Vardenafil, and Avanafil.
  • Soluble Guanylate Cyclase (sGC) Stimulators: This includes the agent Riociguat.

Other Pharmacodynamic and Substance Interactions

The vasodilatory effects may be additive with those of Other Vasodilators and Blood Pressure Lowering Agents, which can result in clinically significant hypotension. Consumption of Alcohol (Ethanol) may similarly enhance or intensify the hypotensive effect.

Additionally, co-administration may cause an increase in the blood level of Dihydroergotamine, leading to an increase in its hypertensive effect.


Timing and Administration Restrictions

Official regulatory guidance mandates specific timing requirements for certain prohibited combinations. For instance, administration of a nitrate must allow a 48-hour separation after the last dose of Tadalafil.

Advertisements

Mechanism of Action

Molecular Bioactivation and Soluble Guanylyl Cyclase (sGC) Activation

This medication functions as a prodrug that requires enzymatic breakdown involving sulfhydryl groups within vascular smooth muscle cells to release its active mediator, Nitric Oxide (NO). The released NO acts directly on the enzyme Soluble Guanylyl Cyclase (sGC), which triggers the cGMP cascade. This molecular sequence is required for the drug to initiate the relaxation of the smooth muscle in blood vessel walls.


Predominant Venodilation and Preload Reduction

The molecular cascade leads to the relaxation of vascular smooth muscle, exhibiting a far greater effect on veins (venodilation) than on arteries. This venodilation increases the capacity of the venous system, reducing the volume and pressure of blood returning to the heart (the preload). This systemic physiological effect directly decreases the cardiac work required of the heart muscle.


Mechanistic Limitation: Tachyphylaxis

The mechanism is subject to a limitation known as nitrate tolerance (tachyphylaxis), where the effect diminishes upon continuous use. This is mechanistically linked to the depletion of the necessary sulfhydryl groups required for NO generation, combined with counter-regulatory activation of the body's vasoconstricting pathways. This constraint on the mechanism establishes the requirement for a drug-free interval to allow the bioactivation machinery to functionally recover.

Advertisements

Dosage and Administration Information

Isosorbide dinitrate administration is structured around two routes: oral for daily maintenance (tablets or extended-release forms) and sublingual for intermittent, rapid use. For chronic regimens, the dosing frequency typically incorporates a nitrate-free interval of at least 14 hours daily to prevent the development of pharmacological tolerance. This scheduling requires careful timing; for instance, twice-daily extended-release doses are separated by several hours to ensure the dose-free period is achieved.

Oral doses, which typically range from 10 mg to 40 mg multiple times daily for immediate-release forms, are preferably taken on an empty stomach (1 hour before or 2 hours after meals). Sublingual administration, used for acute situations, involves placing a 2.5 mg to 5 mg tablet under the tongue and allowing it to dissolve, a dose which may be repeated up to three times within a 15 to 30 minute period. A key administration constraint is that extended-release tablets or capsules must be swallowed whole and must not be crushed or split. For specific populations, such as older adults, treatment is often initiated with caution at the low end of the dosing range.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Изосорбид Динитрат

The research concerning Isosorbide Dinitrate involves various clinical evaluations, primarily focusing on its application in conditions characterized by fluctuating or episodic manifestations of heart disease. The available evidence, sourced from regulatory and scientific documents, contributes to understanding symptom patterns and physiological responses under specific study conditions.


Research Evidence for Stable Angina Pectoris

Isosorbide Dinitrate was studied in research contexts involving fluctuating or unstable symptoms, such as those related to chest pain. Research in this area is mostly derived from short-term, randomized controlled trials (RCTs). Studies monitored how patient-reported outcomes describing perceived discomfort changed during the study period. A primary focus of these trials was measuring functional outcomes, such as the duration of time a patient could exercise before the onset of anginal symptoms during controlled stress testing.

Findings describe patterns observed in the studies where functional measurements suggested differences in exercise capacity compared to placebo in the short term. What remains uncertain is the long-term follow-up in the existing evidence for this medicine in this condition. Research describes patterns where the development of tolerance (a diminished response over time) may affect the interpretation of short-term findings for long-term continuous use.


Research Evidence for Chronic Heart Failure

This section outlines research where Isosorbide Dinitrate was evaluated as part of adjunctive therapy in conditions involving functional limitations, specifically chronic heart failure (CHF) with reduced ejection fraction. Large-scale, long-term randomized controlled trials (RCTs) were conducted, often exploring the medicine in combination with hydralazine, in patients already receiving standard heart failure treatments.

Research examined prognostic endpoints related to systemic or functional imbalance, such as all-cause mortality and heart failure-related hospitalization rates. Findings related to prognostic outcomes are detailed in research exploring the use of the medicine in fixed-dose combination with hydralazine in specific study populations. Data are still emerging, and certainty remains low regarding the observed clinical outcomes of Isosorbide Dinitrate as a monotherapy (used alone) in this setting. Comparative research exploring the use of this medicine alone is limited.


Key Areas of Research Uncertainty and Study Gaps

Research describing the use of Isosorbide Dinitrate highlights several limitations where more information is needed to build a complete picture of the evidence landscape.

  • Monotherapy vs. Combination: Findings related to long-term clinical outcomes in chronic heart failure are predominantly tied to the use of the medicine in combination with hydralazine. Comparative research exploring the use of this medicine as a single agent in this specific setting is limited.
  • Specific Populations: Subgroup findings are uncertain for several populations, and data for certain groups, such as children, remain insufficient. The evidence predominantly relates to Heart Failure with Reduced Ejection Fraction (HFrEF); research exploring patients with Heart Failure with Preserved Ejection Fraction (HFpEF) is ongoing.
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Изосорбид динитрат (FAQ)


Q: What should I do if I forget a dose of my Isosorbide Dinitrate medication?

If a regular dosing schedule is missed, general guidance often states that the missed dose should be taken as soon as it is remembered. However, if the time is close to the next scheduled dose, official information suggests that the missed dose be skipped entirely to avoid the possibility of taking a double dose. Specific details concerning timing rules for a particular dosage form are generally found in the official prescribing information.


Q: Is it possible to become addicted to Isosorbide Dinitrate?

The term addiction is not typically used by regulatory bodies in the context of therapeutic use of organic nitrates like Isosorbide Dinitrate. However, official documentation notes that physical dependence has been observed in industrial workers exposed to very high levels of nitrates over long periods. Under those specific conditions, symptoms such as chest pain were reported upon temporary withdrawal.


Q: What happens if I suddenly stop taking Isosorbide Dinitrate?

Regulatory documents include warnings about the risk of a withdrawal effect when the medicine is stopped abruptly, especially when it has been taken regularly to prevent chest pain. Suddenly stopping the medication can provoke or intensify angina (chest pain) attacks. Any changes to the use of this medicine are typically managed under the guidance of a healthcare professional.


Q: What is the difference between the oral tablet and the sublingual tablet?

The main difference lies in their purpose and speed of action. The sublingual tablet is placed under the tongue for rapid absorption, and it is intended for the immediate relief or prevention of an acute angina attack. The oral tablet is swallowed for general absorption and is typically prescribed for daily maintenance therapy to help reduce the frequency and severity of future attacks over time.


Q: Can Isosorbide Dinitrate affect my sex life?

While regulatory labels do not commonly list changes to libido or sexual function as a frequent side effect, there is a serious, official contraindication concerning its use with certain drugs prescribed for erectile dysfunction. Specifically, it must not be used concurrently with Phosphodiesterase type-5 (PDE-5) inhibitors due to the high risk of severe and dangerous drops in blood pressure.

Advertisements

How should Изосорбид динитрат be stored and disposed of?

Isosorbide Dinitrate Storage and Disposal

Isosorbide dinitrate must be stored under specific environmental and container conditions as defined by regulatory labeling to maintain its stability and efficacy.

Official Storage Requirements

Condition Regulatory Requirement
Temperature Store at controlled room temperature, 20 to 25 C (68 to 77 F); keep away from heat and do not freeze.
Protection Must be protected from light and moisture.
Container Keep in a tightly closed, light-resistant container.
Child Safety Keep out of the reach of children.

Disposal Instructions

Outdated medicine or medicine that is no longer needed must not be kept. Consult a healthcare professional or pharmacist regarding the proper procedure for disposing of any unused or expired isosorbide dinitrate.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Изосорбид динитрат found in:

A-Z Index: